HHS Public Access Author manuscript Author Manuscript

Inflamm Bowel Dis. Author manuscript; available in PMC 2017 July 01. Published in final edited form as: Inflamm Bowel Dis. 2016 July ; 22(7): 1559–1567. doi:10.1097/MIB.0000000000000795.

DNA Methylation and Mutation of Small Colonic Neoplasms in Ulcerative Colitis and Crohn’s Colitis: Implications for Surveillance

Author Manuscript

David H. Johnson, MD1, William R. Taylor, MS1, Mohammed M. Aboelsoud, MB BCh2, Patrick H. Foote, BS1, Tracy C. Yab, BS1, Xiaoming Cao, MD1, Thomas C. Smyrk, MD3, Edward V. Loftus Jr, MD1, Douglas W. Mahoney, MS4, David A. Ahlquist, MD1, and John B. Kisiel, MD1 1Division

of Gastroenterology & Hepatology, Mayo Clinic, Rochester MN

2Department

of Internal Medicine, Rhode Island Memorial Hospital, Pawtucket RI

3Division

of Anatomic Pathology, Mayo Clinic, Rochester MN

4Division

of Biomedical Statistics and Informatics, Mayo Clinic, Rochester MN

Abstract

Author Manuscript

Background—Stool DNA testing in inflammatory bowel disease (IBD) patients may detect colorectal cancer and advanced precancers with high sensitivity; less is known about the presence of DNA markers in small IBD lesions, their association with metachronous neoplasia, or contribution to stool test positivity. Methods—At a single center in two blinded phases, we assayed methylated BMP3 (mBMP3), NDRG4 (mNDRG4), and mutant KRAS in DNA extracted from paraffin-embedded benign lesions and matched control tissues of IBD patients, who were followed for subsequent colorectal dysplasia. Stool samples from independent cases and controls with lesions